Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. bevision

BeVision SIGNED

Better vision after cataract and refractive surgery with photonics technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BeVision project word cloud

Explore the words cloud of the BeVision project. It provides you a very rough idea of what is the project "BeVision" about.

software    solutions    institutes    vision    validate    successful    benefit    imperfections    adaptive    solid    cumulative    aging    satisfied    world    helping    million    prepare    commercialisation    disruptive    4m    surgeries    4    effect    bevision    lens    outcomes    correct    eye    half    innovation    optical    outcome    generating    subsequently    track    profit    interoperable    record    select    clinical    figure    competitive    doctor    fast    forehand    36    6m    voptica    age    validation    introduction    disrupt    refractive    correcting    refine    cataracts    ophthalmic    patient    optics    optimisation    rapid    simulator    older    eyesight    medical    65    protocols    200    as    people    laser    swiftly    commercial    patients    ophthalmology    2025    solution    visual    market    business    actual    vao    clinically    dramatically    skills    manufactures    population    clouding    assembled    objectively    revenue    operation    cataract    suffer    simulate    surgery    post    lenses    understand    device    intraocular    aberrations    billion   

Project "BeVision" data sheet

The following table provides information about the project.

Coordinator		 VOPTICA S.L. 

Organization address
address: CAMPUS DE ESPINARDO, CTRA. MADRID KM.388, PARQUE CIENTIFICO DE MURCIA. EDIFICIO T. LOCALES T1/3 Y T2/9
city: MURCIA
postcode: 30100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.voptica.com
 Total cost 2˙486˙788 €
 EC max contribution 1˙740˙751 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VOPTICA S.L. ES (MURCIA) coordinator 1˙740˙751.00

Map

 Project objective

As we get older, we all will develop eyesight problems. Around the age of 65 more than half of us suffer from eye lens clouding, or cataracts. Cataract surgery is now the most common operation in Europe, with 4.3 million people getting treated each year, a figure that will only increase due to our fast aging population. However, 200,000 of them are not satisfied with the outcome of their eye correcting surgeries as they can’t experience on forehand what their vision will be. Voptica has developed the Visual Adaptive Optics (VAO) simulator, a disruptive innovation in eye testing, allowing patients to experience the effect of intraocular lenses or laser surgery on their vision before the actual operation, helping the patient and doctor to select their best solution and understand what their vision will be like post-surgery.

Our technology is used by world-leading research institutes and lens-manufactures, but to prepare VAO for clinical market introduction our project BeVision will refine its software protocols, make it interoperable and clinically validate the technology. After a successful clinical validation, VAO will be the only medical device in the world that can measure objectively all eye aberrations of patients and, subsequently, simulate the different optical solutions to correct the patient’s eye imperfections during visual testing. Our technology will dramatically improve the outcomes of cataract and laser refractive surgeries.

Our highly competitive technology can swiftly disrupt the $4.4 billion ophthalmology device market, generating a rapid business growth for Voptica, with a cumulative revenue of € 36.4m and a profit of € 8.6m by 2025.

To make BeVision a commercial success, we have assembled a consortium with a solid track record in the development, optimisation, clinical validation and commercialisation of ophthalmic devices and have all the skills and resources for its commercial exploitation to benefit our business and Europe.

 Deliverables

List of deliverables.
WP4 Scientific publications Documents, reports 2020-03-09 16:07:04

Take a look to the deliverables list in detail:  detailed list of BeVision deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BEVISION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BEVISION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More  

JUMPAIR (2018)

Decubitus Ulcers Diseases Diagnoses by means of Smart ICT Anti-Decubitus System based on known Ulcers Activity Biomarkers

Read More